Edoxaban for stroke prevention in atrial fibrillation and age-adjusted predictors of clinical outcomes in routine clinical care

Paulus Kirchhof, L. Pecen, Ameet Bakhai, Carlo de Asmundis, Joris R. de Groot, Jean-Claude Deharo, Peter Kelly, Pierre Lévy, Esteban López-De-Sá, Pedro Monteiro, Jan Steffel, Johannes Waltenberger, Thomas W. Weiss, Petra Laeis, M. C. Manu, J. Souza and Raffaele De Caterina
Additional contact information
Paulus Kirchhof: University Hospital Hamburg-Eppendorf - UKE - Universitaetsklinikum Hamburg-Eppendorf = University Medical Center Hamburg-Eppendorf [Hamburg], DZHK - German Center for Cardiovascular Research - BIH - Berlin Institute of Health, ICAN - Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases - AP-HP - Assistance publique - Hôpitaux de Paris (AP-HP) - INSERM - Institut National de la Santé et de la Recherche Médicale - SU - Sorbonne Université - IHU ICAN - Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] - CHU Pitié-Salpêtrière [AP-HP] - AP-HP - Assistance publique - Hôpitaux de Paris (AP-HP) - SU - Sorbonne Université
L. Pecen: The Czech Academy of Sciences, Institute of Computer Science
Ameet Bakhai: Royal Free London NHS Foundation Trust
Joris R. de Groot: Department of Experimental Cardiology, Amsterdam University Medical Center - UvA - University of Amsterdam [Amsterdam] = Universiteit van Amsterdam
Jean-Claude Deharo: Service de cardiologie - Université de la Méditerranée - Aix-Marseille 2 - APHM - Assistance Publique - Hôpitaux de Marseille - TIMONE - Hôpital de la Timone [CHU - APHM], Département de Cardiologie [Hôpital de la Timone - APHM] - APHM - Assistance Publique - Hôpitaux de Marseille - TIMONE - Hôpital de la Timone [CHU - APHM]
Peter Kelly: The Mater Hospital - Mater Misericordiae University Hospital
Pierre Lévy: Legos - Laboratoire d'Economie et de Gestion des Organisations de Santé - Université Paris Dauphine-PSL - PSL - Université Paris Sciences et Lettres, LEDa - Laboratoire d'Economie de Dauphine - IRD - Institut de Recherche pour le Développement - Université Paris Dauphine-PSL - PSL - Université Paris Sciences et Lettres - CNRS - Centre National de la Recherche Scientifique
Esteban López-De-Sá: Hospital La Paz Institute for Health Research (IdiPAZ), CIBERER U-754, Madrid
Pedro Monteiro: CHUC - Coimbra Hospital and Universitary Centre [Coimbra, Portugal]
Johannes Waltenberger: SyNergy - Munich Cluster for systems neurology [Munich] - TUM - Technische Universität Munchen - Technical University Munich - Université Technique de Munich - LMU - Ludwig Maximilian University [Munich] = Ludwig Maximilians Universität München
Petra Laeis: Daiichi Sankyo Co.
M. C. Manu: Daiichi Sankyo Co.
J. Souza: Daiichi Sankyo Co.

Post-Print from HAL

Abstract: Aims: Patients with atrial fibrillation (AF) treated with oral anticoagulation still suffer from cardiovascular complications including cardiovascular death, stroke, and major bleeding. To identify risk factors for predicting stroke and bleeding outcomes in anticoagulated patients, we assessed 2-year outcomes in patients with AF treated with edoxaban in routine care. We also report the age-adjusted risk predictors of clinical outcomes.Methods and results: The Edoxaban Treatment in Routine Clinical Practice for Patients With Non-Valvular Atrial Fibrillation (ETNA-AF) Europe (NCT02944019) is a prospective, multi-centre, post-authorisation, observational study with an overall 4-year follow-up conducted in 825 centres enrolling edoxaban-treated patients in 10 European countries. Of the 13 133 patients with AF (mean age: 73.6 ± 9.5 years), 5682 (43.3%) were female. At the 2-year follow-up, 9017/13 133 patients were still on edoxaban; 1830 discontinued treatment including 937 who died (annualised event rate of all-cause death was 3.87%). 518 (2.14%) patients died of cardiovascular causes; 234 (0.97%) experienced major bleeding and 168 (0.70%) experienced stroke or systemic embolic events (SEE). Intracranial haemorrhage was noted in 49 patients (0.20%). History of transient ischaemic attack (TIA) at baseline was the strongest predictor of ischaemic stroke or SEE (Wald χ2: 73.63; P

Keywords: Atrial fibrillation; Edoxaban; Non-vitamin K oral anticoagulant; Real-world; Registry (search for similar items in EconPapers)
Date: 2022
References: Add references at CitEc
Citations:

Published in European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 9 (1)

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:hal:journl:hal-04584651

Access Statistics for this paper

More papers in Post-Print from HAL
Bibliographic data for series maintained by CCSD ().